George Lawrence Mikan III - Mar 11, 2025 Form 4 Insider Report for NeueHealth, Inc. (NEUE)

Role
CEO & President, Director
Signature
/s/ Eric Halverson for George Lawrence Mikan III, Attorney-in-Fact
Stock symbol
NEUE
Transactions as of
Mar 11, 2025
Transactions value $
-$117,004
Form type
4
Date filed
3/13/2025, 09:45 PM
Previous filing
Mar 11, 2025
Next filing
Mar 17, 2025
SEC
View on sec.gov

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
transaction NEUE Common Stock Sale -$25.7K -3.75K -2.03% $6.85 181K Mar 11, 2025 Direct F1, F2
transaction NEUE Common Stock Options Exercise +130K +71.84% 311K Mar 11, 2025 Direct F3
transaction NEUE Common Stock Sale -$91.3K -13.2K -4.24% $6.93 298K Mar 12, 2025 Direct F1, F4

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
transaction NEUE Restricted Stock Units Options Exercise $0 -130K -33.33% $0.00 260K Mar 11, 2025 Common Stock 130K Direct F3, F5
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 These shares were sold by the reporting person to cover tax withholding obligations upon the vesting of restricted stock units and were not discretionary transactions by the reporting person.
F2 The reported price in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $6.83 to $6.90 per share. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.
F3 Each restricted stock unit represents a contingent right to receive one share of the Issuer's common stock.
F4 The reported price in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $6.71 to $6.98 per share. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.
F5 These restricted stock units vest in three equal annual installments beginning on March 11, 2025.